Friedman Bart 4

What Happened Bart Friedman, a director of Ovid Therapeutics, was granted a derivative award on 2026-02-26 covering 65,000 shares. The Form 4 reports the grant at $0.00 (no cash paid at grant). This was an award (not a market purchase or sale) and does not generate immediate proceeds.

Key Details

• Transaction date: 2026-02-26; reported on Form 4 filed 2026-03-02 (timely filing).
• Transaction type: A (award/grant) — derivative security (option) for 65,000 shares; reported price $0.00.
• Vesting: The option will vest in full on February 26, 2027, subject to continuous service (footnote F1).
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: Filed within the standard reporting window (Form 4 filed 2026-03-02).

Context This was an equity award (an option grant) tied to continued service as a director and does not represent an immediate purchase or sale of stock. Such grants are commonly used as director compensation; they don’t by themselves indicate a change in insider sentiment or immediate market activity.